Get the Stockscreener App
5.35
1.90%
0.10
After Hours:
5.23
-0.12
-2.24%
Edesa Biotech Inc stock is traded at $5.35, with a volume of 89,224.
It is up +1.90% in the last 24 hours and down -34.68% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$5.25
Open:
$5.35
24h Volume:
89,224
Relative Volume:
0.20
Market Cap:
$51.54M
Revenue:
-
Net Income/Loss:
$-10.44M
P/E Ratio:
-3.9908
EPS:
-1.3406
Net Cash Flow:
$-7.72M
1W Performance:
-8.08%
1M Performance:
-34.68%
6M Performance:
+287.68%
1Y Performance:
+124.79%
1-Day Range:
$5.12
$5.5168
1-Week Range:
$5.12
$6.60
52-Week Range:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
5.35 | 50.57M | 0 | -10.44M | -7.72M | -1.3406 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Biotech Inc (EDSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edesa Biotech Inc (EDSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edesa Biotech Inc (EDSA) Income Statement - TradingKey
Edesa Biotech Market Sentiment - Benzinga España
Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EDSA|Edesa Biotech Inc|Price:5.250|Chg%:-0.410 - TradingKey
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
TradingKey - TradingKey
Edesa Biotech, Inc. Revenue Breakdown – NASDAQ:EDSA - TradingView
Edesa Biotech Inc (EDSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech (EDSA) Revenue BreakdownMain Composition - Moomoo
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal - Stocktwits
Edesa Biotech, Inc. SEC Filing (Jul 14, 2026) - Stock Titan
Edesa Biotech (EDSA) Declines 2.85% as Shares Approach Key Support ZoneGamma Flip Level - dars.gov.et
Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resale - Stock Titan
Edesa Biotech | 424B3: Prospectus - Moomoo
Enterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
Edesa Biotech Company Profile & Introduction - Moomoo
Edesa Biotech | 4: Statement of changes in beneficial ownership of securities-Officer Nijhawan Pardeep - Moomoo
EDSA Should I Buy - Intellectia AI
Form S-3 EDESA BIOTECH For: 2 July By Investing.com - Investing.com Nigeria
Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant - Stock Titan
Edesa Biotech (NASDAQ: EDSA) registers 729,241 shares for resale - Stock Titan
EDSA: Positive Exploratory Data in Patients with AKI - Yahoo Finance
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesShare Repurchase Impact - dars.gov.et
Brookline Capital Initiates Edesa Biotech(EDSA.US) With Buy Rating, Announces Target Price $21 - Moomoo
Brookline initiates Edesa Biotech stock with buy on pipeline By Investing.com - Investing.com Nigeria
Brookline initiates Edesa Biotech stock with buy on pipeline - Investing.com
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues R&D spendingMargin Guidance - dars.gov.et
Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edesa Biotech, Inc. Actuals & Estimates (NASDAQ:EDSA) - TradingView
Price to book forward of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
EDSA Forecast — Price Target — Prediction for 2027 - TradingView
Edesa Biotech Inc (EDSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edesa Biotech Inc (EDSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: EPS Misses Estimates as Company Continues Pipeline DevelopmentGuidance Revision Trend - dars.gov.et
CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares - simplywall.st
EDSA Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossGuidance vs Actual - dars.gov.et
Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group - Stock Titan
Edesa Biotech announces $3.5M PIPE financing - MSN
Edesa Biotech Inc (EDSA) Institutional Confidence - TradingKey
Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edesa Biotech (EDSA) Surges 9.73%: Breaking Above Key Support LevelsDemand Zone - DonanımHaber
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):